Pulse Biosciences Announces Clinical Data Highlighting its nPulse™ Cardiac Surgical System to be Presented at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting
Pulse Biosciences Press Release
HAYWARD, Calif. -- Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced the upcoming presentation of early clinical data on the treatment of atrial fibrillation (AF) using the nPulse™ Cardiac Surgical System at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting from October 8-11th in Copenhagen, Denmark.
“The FDA’s recent approval of our IDE study for the nPulse™ Cardiac Surgical System marks a significant milestone in the development of our novel technology for the treatment of atrial fibrillation," said Paul LaViolette, Co-Chairman and CEO of Pulse Biosciences. “We are excited for the early clinical evidence supporting the safety and efficacy of nPulse™ to be featured at the world’s largest cardiothoracic surgery meeting and we appreciate the dedication of the clinicians continuing to evaluate and utilize our platform.”
Events highlighting the nPulse™ Cardiac Surgical System, using nanosecond PFA energy for the treatment of AF, include:
|
Wednesday, October 8th, 2025 |
|
Acquired Cardiac Techno-College – Part 1 |
|
Presentation | Pulsed Field Ablation (Live in a box 3D) |
|
Time: 9:30am – 12:30 pm (Presentation @ 10:40) |
|
Location: Bella Center Copenhagen, Hall A1 |
|
Bart van Putte, MD, St. Antonius Hospital, Nieuwegein, The Netherlands |
|
Friday, October 10th, 2025 |
|
Thoracic Moderated e-Poster Presentation | First-In-Human Study Using Nanosecond Pulsed Field Ablation (nsPFA) for Surgical Left Atrial Box Isolation with Electroanatomical Mapping Follow-up |
|
Time: 12:30pm – 1:00 pm |
|
Location: Bella Center Copenhagen, Moderated e-Poster Station 2 |
|
Bart van Putte, MD, St. Antonius Hospital, Nieuwegein, The Netherlands |
About Pulse Biosciences®
Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as the potential to improve the quality of life for patients. The Company’s proprietary nPulse™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its nPulse technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation.
Pulse Biosciences, nPulse, Vybrance, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA, nanosecond PFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.
Related Content
